Factors Affectıng Sentinel Lymph Node Metastasis in Patients wıth Breast Cancer Undergoıng Sentinel Lymph Node Biopsy before or after Systemic Therapy


breast Cancer
Sentinel lymph node
Axillary dissection

How to Cite

Sagdic, M. F., Yuksel, C., Culcu, S., Aksel, B. ., Ozaslan, C. ., Kutun, S. ., & Dogan, L. (2021). Factors Affectıng Sentinel Lymph Node Metastasis in Patients wıth Breast Cancer Undergoıng Sentinel Lymph Node Biopsy before or after Systemic Therapy. Iranian Red Crescent Medical Journal, 23(10). https://doi.org/10.32592/ircmj.2021.23.10.1086


Background: The tendency to spread to sentinel lymph node (SLN) may differ depending on the biological, clinical, and histopathological features of tumors. If the factors that affect SLN metastasis (SLNM) are known, there may be no need to perform SLN biopsy (SLNB) in some groups.

Objectives: This study aimed to investigate the factors affecting SLNM in patients who underwent surgery and SLNB before (surgery group) or after (neoadjuvant chemotherapy group) systemic therapy in the light of current biological characteristics of tumors and patients.

Methods: The study included patients who were operated on for breast cancer and underwent SLNB in our institute between 2017 and 2019. The study included a total of 1,050 patients, who were divided into the surgery (n=900) and neoadjuvant chemotherapy (NAC) groups (n=150). The patients' tumor localization, tumor size, histological subtype, grade, receptor status, lymphovascular invasion (LVI) status, the number of sentinel lymph nodes removed, metastatic lymph nodes in SLNB, and axillary dissection status were analyzed in this study.

Results: The study included a total of 1,050 patients, who were assigned to the surgery (n=900) and NAC groups (n=150). Of the patients, 311 (34.5%) cases had SLNM. In the surgery group, multivariate analyses showed that grade III, LVI, Her2 (+) increased the risk of metastasis. In the NAC group, the analyses showed Pre-NAC clinical findings of LN metastasis and luminal A subtypes as effective factors. The factors affecting SLNM were analyzed, and the univariate analyses showed that grades II and III, a tumor size of>2 cm, LVI, Her2 (+), and triple negative increased the risk of metastasis. The analyses also revealed LVI as the most important risk factor for SLN metastasis.

Conclusion: Knowing the factors affecting SLNM can provide clues for the type of intervention, reconstruction, and radiotherapy planning of patients to be operated on directly or after NAC. In our study, it was found that patient age, tumor size, tumor biology, tumor grade, and especially LVI status were very important in predicting SLN positivity. It is believed that these features should be taken into account when determining the treatment strategy.



  1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of surgery. 1994;220(3):391-8; discussion 8-401. doi:  10.1097/00000658-199409000-00015
  2. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical oncology. 1993;2(6):335-9; discussion 40. .doi: 10.1016/0960-7404(93)90064-6
  3. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. Jama. 2017;318(10):918-26. doi:10.1001/jama.2017.11470
  4. Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, et al. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. JAMA surgery. 2020;155(3):e195410. doi: 10.1001/jamasurg.2019.5410
  5. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, et al. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA surgery. 2017;152(7):665-70. doi: 10.1001/jamasurg.2017.0562
  6. Spring LM, Fell G, Arfe A, Sharma C, Greenup RA, Reynolds KL, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clinical Cancer Research. 2020;26(12):2838-2848 doi: 10.1158/1078-0432.CCR-19-3492
  7. Mitchell RB, Archer SM, Ishman SL, Rosenfeld RM, Coles S, Finestone SA, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg. 2019;160(1_suppl):S1-S42.
  8. Luini A, Gatti G, Ballardini B, Zurrida S, Galimberti V, Veronesi P, et al. Development of axillary surgery in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2005;16(2):259-62. doi: 10.1177/0194599818801757
  9. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The lancet oncology. 2010;11(10):927-33. doi: 10.1016/S1470-2045(10)70207-2
  10. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569-75. doi:  10.1001/jama.2011.90
  11. Tvedskov TF, Jensen M-B, Ejlertsen B, Christiansen P, Balslev E, Kroman N et al. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study. Breast cancer research and treatment. 2015;153(3):599-606. doi:https://doi.org/10.1007/s10549-015-3560-7
  12. Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruneri G, Paganelli G, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103(3):492-500. doi: 10.1002/cncr.20809
  13. Yoshihara E, Smeets A, Laenen A, Reynders A, Soens J, Van Ongeval C, et al. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast (Edinburgh, Scotland). 2013;22(3):357-61. doi:10.1016/j.breast.2012.09.003
  14. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). The Breast. 2012;21(5):678-81. doi: 10.1016/j.breast.2012.06.013
  15. Sackey H, Johansson H, Sandelin K, Liljegren G, MacLean G, Frisell J, et al. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015;41(4):577-84. doi: 10.1016/j.ejso.2014.12.006
  16. Sackey H, Magnuson A, Sandelin K, Liljegren G, Bergkvist L, Fülep Z, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. The British journal of surgery. 2014;101(4):390-7. doi:10.1002/bjs.9401
  17. Malter W, Hellmich M, Badian M, Kirn V, Mallmann P, Krämer S, et al. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer. Anticancer research. 2018;38(6):3657-62. doi: 10.21873/anticanres.12642  
  18. Fujii T, Yajima R, Yamaguchi S, Yanagita Y, Fujisawa T, Hirakata T, et al. Extracapsular invasion of sentinel lymph nodes is not associated with disease recurrence in breast cancer. International surgery. 2014;99(4):305-8. doi:  10.9738/INTSURG-D-13-00012.1
  19. Yajima R, Fujii T, Yanagita Y, Fujisawa T, Miyamoto T, Hirakata T, et al. Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Annals of surgical oncology. 2015;22(1):52-8. doi: 10.1245/s10434-014-3941-x
  20. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Annals of the New York Academy of Sciences. 2008;1131(1):225-34. doi:10.1196/annals.1413.020
  21. Ejlertsen B, Jensen M-B, Rank F, Rasmussen BB, Christiansen P, Kroman N, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. JNCI: Journal of the National Cancer Institute. 2009;101(10):729-35. doi: 10.1093/jnci/djp090
  22. Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670-80. doi: 10.1002/cncr.26711
  23. Cornwell LB, McMasters KM, Chagpar AB. The impact of lymphovascular invasion on lymph node status in patients with breast cancer. The American surgeon. 2011;77(7):874-7. doi:10.1177/000313481107700722
  24. Diotaiuti S, De Summa S, Altieri R, Dantona C, Tommasi S, Di Gennaro M, et al. Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncology letters. 2020;20(3):2469-76. doi: 10.3892/ol.2020.11793     
  25. Ozemir I, Orhun K, Eren T, Baysal H, Sagiroglu J, Leblebici M, et al. Factors affecting sentinel lymph node metastasis in Turkish breast cancer patients: Predictive value of Ki-67 and the size of lymph node. Bratislavske lekarske listy. 2016;117(8):436-41. doi:  10.4149/bll_2016_085.
  26. Ugras S, Stempel M, Patil S, Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Annals of surgical oncology. 2014;21(12):3780-6. doi: 10.1245/s10434-014-3851-y
  27. Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clinical breast cancer. 2008;8(3):249-56. . doi: 10.3816/CBC.2008.n.028
  28. Gangi A, Mirocha J, Leong T, Giuliano AE. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. Ann Surg Oncol. 2014;21(13):4098-103. doi: 10.1245/s10434-014-3989-7
  29. Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. Journal of breast cancer. 2015;18(2):143-8. doi:  10.4048/jbc.2015.18.2.143
  30. Ding J, Jiang L, Wu W. Predictive Value of Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in Early Breast Cancer. Medical science monitor : international medical journal of experimental and clinical research. 2017;23:4102-8. . doi:10.12659/MSM.902795
  31. Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR. The impact of histopathology on nodal metastases in minimal breast cancer. Archives of surgery (Chicago, Ill : 1960). 1997;132(4):384-90 doi: 10.1001/archsurg.1997.01430280058008
  32. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP,et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. Journal of the American College of Surgeons. 2000;191(1):1-6; discussion -8. doi:  10.1016/s1072-7515(00)00310-0
  33. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World journal of surgery. 2001;25(6):767-72. doi: : 10.1007/s00268-001-0003-x
  34. Cutuli B, Velten M, Martin C. Assessment of axillary lymph node involvement in small breast cancer: analysis of 893 cases. Clinical breast cancer. 2001;2(1):59-65. doi:  10.3816/CBC.2001.n.012
  35. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, et al. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?. Annals of surgical oncology. 2014;21(8):2468-73. doi:  10.1245/s10434-014-3775-6
  36. Boileau J-F, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. Journal of Clinical Oncology. 2015;33(3):258-64. doi:  10.1200/JCO.2014.55.7827
  37. de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. Bmc Cancer. 2017;17(1):1-7. doi:10.1186/s12885-017-3361-y
  38. Murphy BL, Hoskin TL, Day C, Habermann EB, Boughey JC. Preoperative prediction of node-negative disease after neoadjuvant chemotherapy in patients presenting with node-negative or node-positive breast cancer. Annals of Surgical Oncology. 2017;24(9):2518-25. doi:  10.1245/s10434-017-5872-9